TARS Q2 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M

Gross Profit

$38M92.6% margin

Operating Income

-$33M-81.6% margin

Net Income

-$33M-81.6% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

+47.8%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$377M

Total Liabilities

$125M

Stockholders' Equity

$252M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$0	—
Gross Profit	$38M	-$316,000	+12064.9%
Operating Income	-$33M	-$33M	-1.5%
Net Income	-$33M	-$31M	-5.9%

Revenue Segments

Product

$41M100%